Related Experiment Video
Updated: Aug 5, 2025

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Beta-Lactam Probability of Target Attainment Success: Cefepime as a Case Study
Daniel J Selig1, Adrian T Kress1, Robert J Nadeau1
1Walter Reed Army Institute of Research, Experimental Therapeutics Branch, Silver Spring, MD 20910, USA.
Introduction:
Probability of target attainment (PTA) analysis using Monte Carlo simulations has become a mainstay of dose optimization. We highlight the technical and clinical factors that may affect PTA for beta-lactams.
Methods:
We performed a mini review in adults to explore factors relating to cefepime PTA success and how researchers incorporate PTA into dosing decisions. In addition, we investigated, via simulations with a population pharmacokinetic (PK) model, factors that may affect cefepime PTA success.
Results:
The mini review included 14 articles. PTA results were generally consistent, given the differences in patient populations. However, dosing recommendations were more varied and appeared to depend on the definition of pharmacodynamic (PD) target, definition of PTA success and specific clinical considerations. Only 3 of 14 articles performed formal toxicological analysis. Simulations demonstrated that the largest determinants of cefepime PTA were the choice of PD target, continuous vs. intermittent infusion and creatinine clearance. Assumptions for protein binding, steady state vs. first dose, and simulating different sampling schemes may impact PTA success under certain conditions. The choice of one or two compartments had a minimal effect on PTA.
Conclusions:
PTA results may be similar with different assumptions and techniques. However, dose recommendation may differ significantly based on the selection of PD target, definition of PTA success and considerations specific to a patient population. Demographics and the PK parameters used to simulate time-concentration profiles should be derived from patient data applicable to the purpose of the PTA. There should be strong clinical rationale for dose selection. When possible, safety and toxicity should be considered in addition to PTA success.
More Related Videos
Related Concept Videos
Antimicrobial Effectiveness
Urine Studies II: Urine Culture and Sensitivity Test
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Acute Pyelonephritis II: Diagnostic Studies and Management

